Mumbai-based pharmaceutical company Cipla has announced that it has cut the price for three more cancer drugs by nearly 64 percent.
The three drugs, Erlocip, Docetax and Capegard, are used in treating lung and pancreatic cancer, breast cancer, head and neck cancer, gastric cancer, bladder and colorectal and colon cancers.
AdvertisementAccording to the revised prices, Erlocip will now cost Rs 9,900 for 30 tablets compared to the earlier price of Rs 27,000, Docetax price has been reduced from Rs 3,300 to Rs 1,650 while Capegard will cost Rs 600 instead of Rs 1,200. The price slash comes just a few months after Cipla had reduced the prices for other cancer drugs.
"We have had a good quarter this time and it has been 15 years since we started the Cipla Palliative Care Centre, so it was the right time to announce this. Continuing its contribution towards affordable and accessible treatment for patients, Cipla extends the work done in HIV/AIDS and malaria to include cancer, not only in India but globally", Cipla chairman Y K Hamied said.
P Simple Test Can Predict Diabetes Risk Ten Years In Advance Child Care Centers Have A Role To Play In Curbing Childhood Obesity M
You May Also Like